gc012f
gracell
[]
fastcar-t process provides next-day car t manufacturing with a high (93%) overall response rate in 29 patients. phase i/ii studies are now beginning in the us. #asco23 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.